Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: J Heart Lung Transplant. 2010 Jun 16;29(9):973–980. doi: 10.1016/j.healun.2010.05.006

Figure 4.

Figure 4

Survival. Recipients who developed DSA and were treated with IVIG alone had a significantly worse survival than those treated with IVIG and rituximab (A). There was no significant survival difference between those who developed DSA to Class I, Class II, or both Class I and Class II antigens (B). Recipients who had persistent DSA had a significantly worse survival than those who cleared the DSA (C).